Pyxis Oncology (PYXS) Interim CEO Thomas Civik Receives Award of 250,956 Shares

What Happened

• Thomas Civik, Interim Chief Executive Officer and Director of Pyxis Oncology (PYXS), was reported to have acquired 250,956 shares on August 12, 2026. The transaction is reported as an award/grant (derivative) with an acquisition price of $0.00, reflecting the vesting of a performance-based portion of an option.

Key Details

• Transaction date: August 12, 2026; Report filed: August 14, 2026 (timely report).
• Transaction type/code: Award/Grant (A) — derivative acquisition reported at $0.00 for 250,956 shares.
• Shares owned after transaction: Not specified in the Form 4 filing.
• Footnote: The shares represent the performance-based portion of an option granted February 3, 2026, which vested in full upon completion of a successful financing or strategic transaction. The Board determined the performance conditions were met on August 12, 2026.
• No sale reported — the filing indicates vesting/acquisition only, not an immediate sale or cashless exercise.

Context

• This was a performance-vested award from an earlier option grant rather than an open-market purchase or sale. Such vesting events reflect contractual compensation or incentive conditions being met; they do not, by themselves, indicate the insider is buying or selling company stock on the market.